Eyetech Pharmaceuticals Inc., of New York, appointed Charles Williams senior vice president, manufacturing.

Genta Inc., of Berkeley Heights, N.J., appointed Jerome Groopman, to its board.

Georgia Biomedical Partnership, of Atlanta, appointed Jack Spencer president.

Guilford Pharmaceuticals Inc., of Baltimore, appointed Michael Kelly vice president of sales and marketing.

Gyros AB, of Uppsala Science Park, Sweden, appointed Winfried Girg sales manager for its Munich, Germany-based subsidiary.

InKine Pharmaceutical Co. Inc., of Blue Bell, Pa., elected Norman Schellenger to its board.

InterMune Inc., of Brisbane, Calif., promoted Brian Murphy to vice president of marketing and commercial strategy, hepatology.

Myriad Genetics Inc., of Salt Lake City, named Richard Marsh vice president, general counsel and secretary.

Nabi Biopharmaceuticals, of Boca Raton, Fla., appointed Daniel Greenleaf senior vice president, operations.

Nabi Biopharmaceuticals, of Boca Raton, Fla., promoted Thomas McLain to president and chief operating officer.

Neurogen Corp., of Branford, Conn., appointed Charles Ritrovato vice president, drug regulatory affairs.

New York Biotechnology Association in Hawthorne, N.Y., elected Ron Cohen as chairman for the 2003 to 2004 term.

Oxxon Pharmaccines Ltd., of Oxford, UK, formed a scientific advisory board, consisting of Adrian Hill as chairman, Leszek Borysiewicz, Wayne Koff, Andrew McMichael, Howard Thomas and Jeffrey Weber.